Adela Rambi Cardones
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Adela Rambi Cardones has a total of 169 co-authors. Here are the top co-authors by number of shared publications:
- Nelson J. Chao
Duke University Medical Center, Durham, North Carolina, United States
5 shared publications - Russell P. Hall
Department of Dermatology, Duke University School of Medicine, Durham, North Carolina, USA
5 shared publications - Jennifer Y. Zhang
Department of Dermatology, Duke University Medical Center
3 shared publications Krystina Quow
Department of Dermatology Duke University Medical Center Durham NC USA
3 shared publications- Aikaterini Patsatsi
Second Department of Dermatology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
2 shared publications - Amber Fresco
Department of Dermatology Duke University Medical Center Durham NC USA
2 shared publications
Latest Publications
- Open Access
- 28 October 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 67, 115-116
Intravenous immunoglobulin for cutaneous chronic graft-versus-host disease
- 28 October 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 67, 115-116
Open AccessIntravenous immunoglobulin for cutaneous chronic graft-versus-host disease
- Open Access
- 28 April 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (9) , 2173-2182
Cutaneous dysbiosis characterizes the post–allogeneic hematopoietic stem cell transplantation period
Gut dysbiosis is linked to mortality and the development of graft-versus-host disease after hematopoietic stem cell transplantation (HSCT), but the impact of cutaneous dysbiosis remains unexplored. We performed a pilot observational study, obtained retroauricular and forearm skin swabs from 12 adult patients before conditioning chemotherapy/radiation and at 1 week, 1 month, and 3 months after allogeneic HSCT, and performed shotgun metagenomic sequencing. The cutaneous microbiome among HSCT patients was enriched for gram-negative bacteria such as Escherichia coli and Pseudomonas, fungi, and viruses. Enrichment with bacteriophages and Polyomavirus species was observed among patients who died within 1 year. We observed longitudinal stability of the cutaneous microbiome at the 3-month time point among those who survived beyond 1 year after HSCT, although these may simply be a reflection of the overall medical status of the patients. There was no association with fungal abundance and any of the outcomes observed. The cutaneous microbiome may be a reservoir of pathobionts among allogeneic HSCT patients. Our findings suggest that cutaneous dysbiosis exists after HSCT, but the ultimate implication of this to patient outcomes remains to be seen through larger studies.
- 28 April 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (9) , 2173-2182
Open AccessCutaneous dysbiosis characterizes the post–allogeneic hematopoietic stem cell transplantation period
Gut dysbiosis is linked to mortality and the development of graft-versus-host disease after hematopoietic stem cell transplantation (HSCT), but the impact of cutaneous dysbiosis remains unexplored. We performed a pilot observational study, obtained retroauricular and forearm skin swabs from 12 adult patients before conditioning chemotherapy/radiation and at 1 week, 1 month, and 3 months after allogeneic HSCT, and performed shotgun metagenomic sequencing. The cutaneous microbiome among HSCT patients was enriched for gram-negative bacteria such as Escherichia coli and Pseudomonas, fungi, and viruses. Enrichment with bacteriophages and Polyomavirus species was observed among patients who died within 1 year. We observed longitudinal stability of the cutaneous microbiome at the 3-month time point among those who survived beyond 1 year after HSCT, although these may simply be a reflection of the overall medical status of the patients. There was no association with fungal abundance and any of the outcomes observed. The cutaneous microbiome may be a reservoir of pathobionts among allogeneic HSCT patients. Our findings suggest that cutaneous dysbiosis exists after HSCT, but the ultimate implication of this to patient outcomes remains to be seen through larger studies.
- Open Access
- 25 April 2025
- Published by Elsevier in JID Innovations
- Vol. 5 (4) , 100373
Insights into Keratinocyte and Immunologic Landscape in Cutaneous Graft-Versus-Host Disease through Single-Cell Transcriptomics
- 25 April 2025
- Published by Elsevier in JID Innovations
- Vol. 5 (4) , 100373
Open AccessInsights into Keratinocyte and Immunologic Landscape in Cutaneous Graft-Versus-Host Disease through Single-Cell Transcriptomics
- 3 March 2025
- Published by Springer Nature in Nature Reviews Disease Primers
- Vol. 11 (1) , 16
Author Correction: Bullous pemphigoid
- 3 March 2025
- Published by Springer Nature in Nature Reviews Disease Primers
- Vol. 11 (1) , 16
Author Correction: Bullous pemphigoid
- Top Cited Papers
- 20 February 2025
- Published by Springer Nature in Nature Reviews Disease Primers
- Vol. 11 (1) , 1-19
Bullous pemphigoid
Bullous pemphigoid is a chronic, subepidermal autoimmune blistering disease characterized by tense blisters on erythematous or normal skin that predominantly affects the older population. The disease arises from autoantibodies targeting hemidesmosomal proteins BP180 and BP230, which are crucial for dermal–epidermal adhesion. The incidence of bullous pemphigoid is increasing, attributed to an ageing population and improved diagnostic recognition. Genetic predisposition, environmental triggers and associations with other autoimmune disorders underline its multifactorial nature. Diagnosis involves clinical presentation, histopathology, direct immunofluorescence and serological tests. Treatment aims to reduce symptoms and prevent new blister formation, using corticosteroids, immunosuppressive agents and biologics such as rituximab and omalizumab. Despite therapeutic advancements, challenges persist in long-term management, especially in older patients with comorbidities. Ongoing research into molecular mechanisms and novel therapeutic targets and clinical trials are crucial for the development of safer and more effective treatments.
- 20 February 2025
- Published by Springer Nature in Nature Reviews Disease Primers
- Vol. 11 (1) , 1-19
Top Cited PapersBullous pemphigoid
Bullous pemphigoid is a chronic, subepidermal autoimmune blistering disease characterized by tense blisters on erythematous or normal skin that predominantly affects the older population. The disease arises from autoantibodies targeting hemidesmosomal proteins BP180 and BP230, which are crucial for dermal–epidermal adhesion. The incidence of bullous pemphigoid is increasing, attributed to an ageing population and improved diagnostic recognition. Genetic predisposition, environmental triggers and associations with other autoimmune disorders underline its multifactorial nature. Diagnosis involves clinical presentation, histopathology, direct immunofluorescence and serological tests. Treatment aims to reduce symptoms and prevent new blister formation, using corticosteroids, immunosuppressive agents and biologics such as rituximab and omalizumab. Despite therapeutic advancements, challenges persist in long-term management, especially in older patients with comorbidities. Ongoing research into molecular mechanisms and novel therapeutic targets and clinical trials are crucial for the development of safer and more effective treatments.
- 13 September 2023
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 49 (12) , 1200-1202
Persistent Vascular Steal Syndrome Causing a Nonhealing Wound After Mohs Micrographic Surgery
- 13 September 2023
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 49 (12) , 1200-1202
Persistent Vascular Steal Syndrome Causing a Nonhealing Wound After Mohs Micrographic Surgery
- Open Access
- 2 May 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (11)
Single-cell landscape analysis unravels molecular programming of the human B cell compartment in chronic GVHD
Alloreactivity can drive autoimmune syndromes. After allogeneic hematopoietic stem cell transplantation (allo-HCT), chronic graft-versus-host disease (cGVHD), a B cell–associated autoimmune-like syndrome, commonly occurs. Because donor-derived B cells continually develop under selective pressure from host alloantigens, aberrant B cell receptor (BCR) activation and IgG production can emerge and contribute to cGVHD pathobiology. To better understand molecular programing of B cells in allo-HCT, we performed scRNA-Seq analysis on high numbers of purified B cells from patients. An unsupervised analysis revealed 10 clusters, distinguishable by signature genes for maturation, activation, and memory. Within the memory B cell compartment, we found striking transcriptional differences in allo-HCT patients compared with healthy or infected individuals, including potentially pathogenic atypical B cells (ABCs) that were expanded in active cGVHD. To identify intrinsic alterations in potentially pathological B cells, we interrogated all clusters for differentially expressed genes (DEGs) in active cGVHD versus patients who never had signs of immune tolerance loss (no cGVHD). Active cGVHD DEGs occurred in both naive and BCR-activated B cell clusters. Remarkably, some DEGs occurred across most clusters, suggesting common molecular programs that may promote B cell plasticity. Our study of human allo-HCT and cGVHD provides understanding of altered B cell memory during chronic alloantigen stimulation.
- 2 May 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (11)
Open AccessSingle-cell landscape analysis unravels molecular programming of the human B cell compartment in chronic GVHD
Alloreactivity can drive autoimmune syndromes. After allogeneic hematopoietic stem cell transplantation (allo-HCT), chronic graft-versus-host disease (cGVHD), a B cell–associated autoimmune-like syndrome, commonly occurs. Because donor-derived B cells continually develop under selective pressure from host alloantigens, aberrant B cell receptor (BCR) activation and IgG production can emerge and contribute to cGVHD pathobiology. To better understand molecular programing of B cells in allo-HCT, we performed scRNA-Seq analysis on high numbers of purified B cells from patients. An unsupervised analysis revealed 10 clusters, distinguishable by signature genes for maturation, activation, and memory. Within the memory B cell compartment, we found striking transcriptional differences in allo-HCT patients compared with healthy or infected individuals, including potentially pathogenic atypical B cells (ABCs) that were expanded in active cGVHD. To identify intrinsic alterations in potentially pathological B cells, we interrogated all clusters for differentially expressed genes (DEGs) in active cGVHD versus patients who never had signs of immune tolerance loss (no cGVHD). Active cGVHD DEGs occurred in both naive and BCR-activated B cell clusters. Remarkably, some DEGs occurred across most clusters, suggesting common molecular programs that may promote B cell plasticity. Our study of human allo-HCT and cGVHD provides understanding of altered B cell memory during chronic alloantigen stimulation.
- 11 April 2023
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 89 (2) , 390-392
Pilot, open-label, single-arm clinical trial evaluating the efficacy of topical crisaborole for steroid refractory morphea
- 11 April 2023
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 89 (2) , 390-392
Pilot, open-label, single-arm clinical trial evaluating the efficacy of topical crisaborole for steroid refractory morphea
- 1 April 2023
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 2 (4)
Cutaneous Vasculopathy and Recalcitrant Lower-Extremity Ulcerations
- 1 April 2023
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 2 (4)
Cutaneous Vasculopathy and Recalcitrant Lower-Extremity Ulcerations
- 1 March 2023
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 9 (3) , 432-433
A Case of Multiple Hemorrhagic Friable Nodules
A man in his 50s presented with bleeding wounds and nodules on the bilateral hips and forearms. He previously received failed systemic and radiation therapy for tumor stage mycosis fungoides (MF). He had received 11 courses of extended beam radiation therapy, including 3 courses of total skin irradiation of 24 to 30 Gy, and focal irradiation to the left posterior thigh and hip/buttock with 2.5/3 Gy to 12.5/24 Gy, respectively, and the right posterior thigh and hip with 2 Gy to 20 and 26 Gy, respectively. Seven years before this visit, he underwent a reduced-intensity, matched, unrelated donor, allogeneic hematopoietic stem cell transplant (HSCT). His post-transplant course was complicated by severe chronic graft vs host disease of the skin, eyes, and gut, for which he received systemic corticosteroid therapy, tacrolimus, methotrexate, and long-term extracorporeal photopheresis. Three years after the HSCT, he developed chronic ulcerations on the hips, back, and arms at the site of previously irradiated tumors, as well as multiple friable, hemorrhagic, and bleeding nodules on bilateral hips and his forearms while receiving treatment with corticosteroids and extracorporeal photopheresis. He underwent several debulking procedures and excision biopsies of the nodules, which revealed granulation tissue on histology. In this latest visit, physical examination revealed recurrent hemorrhagic and friable nodules on his left lateral hip and left lateral buttock (Figure 1). Similar nodules were noted on his right hip and forearm. The patient underwent repeated debulking and biopsy. He was also treated with micafungin, amphotericin B, levofloxacin, dapsone, acyclovir, pentamidine, penicillin VK, and posaconazole. Positron emission tomography (PET) computed tomography (CT) results did not show evidence of visceral or extracutaneous disease.
- 1 March 2023
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 9 (3) , 432-433
A Case of Multiple Hemorrhagic Friable Nodules
A man in his 50s presented with bleeding wounds and nodules on the bilateral hips and forearms. He previously received failed systemic and radiation therapy for tumor stage mycosis fungoides (MF). He had received 11 courses of extended beam radiation therapy, including 3 courses of total skin irradiation of 24 to 30 Gy, and focal irradiation to the left posterior thigh and hip/buttock with 2.5/3 Gy to 12.5/24 Gy, respectively, and the right posterior thigh and hip with 2 Gy to 20 and 26 Gy, respectively. Seven years before this visit, he underwent a reduced-intensity, matched, unrelated donor, allogeneic hematopoietic stem cell transplant (HSCT). His post-transplant course was complicated by severe chronic graft vs host disease of the skin, eyes, and gut, for which he received systemic corticosteroid therapy, tacrolimus, methotrexate, and long-term extracorporeal photopheresis. Three years after the HSCT, he developed chronic ulcerations on the hips, back, and arms at the site of previously irradiated tumors, as well as multiple friable, hemorrhagic, and bleeding nodules on bilateral hips and his forearms while receiving treatment with corticosteroids and extracorporeal photopheresis. He underwent several debulking procedures and excision biopsies of the nodules, which revealed granulation tissue on histology. In this latest visit, physical examination revealed recurrent hemorrhagic and friable nodules on his left lateral hip and left lateral buttock (Figure 1). Similar nodules were noted on his right hip and forearm. The patient underwent repeated debulking and biopsy. He was also treated with micafungin, amphotericin B, levofloxacin, dapsone, acyclovir, pentamidine, penicillin VK, and posaconazole. Positron emission tomography (PET) computed tomography (CT) results did not show evidence of visceral or extracutaneous disease.